Improved tumor localization and radioimaging with chemically modified monoclonal antibodies

Cancer Biotherapy and Radiopharmaceuticals

Volumn 11, Issue 3, 1996, Pages 203-216

  Khawli, Leslie A ^a   Glasky, Michelle S ^a   Alauddin, Mian M ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD VESSEL PERMEABILITY; CHEMICAL MODIFICATION; CROSS LINKING; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; PRIORITY JOURNAL; RECEPTOR AFFINITY; TUMOR GROWTH; TUMOR LOCALIZATION;

EID: 0029776847     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1996.11.203     Document Type: Article

References (45)

1. Kosmas C, Linardou H, and Epenetos AA Review: Advances in monoclonal antibody tumour targeting. J Drug Target 1993;1:81-91.
2. Buchsbaum DJ and Lawrence TS. Tumor therapy with radiolabeled monoclonal antibodies. Antibod Immunoconj Radiopharm 1991;4:245-272.
3. Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J Med 1993;94:297-312.
4. Foon KA Biological response modifiers: The new immunotherapy. Cancer Res 1989;49:1621-1639.
5. Jain RK. Transport of molecules across tumor vasculature. Cancer and Metastasis Rev 1987,6:559-593.
6. Jain RK. Determinants of tumor blood flow A review. Cancer Res 1988;48:2641-2658.
7. Jain RK. Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies J Natl Cancer Inst 1989;81:570-576.
8. Cobb LM. Intratumor factors influencing the access of antibody to tumor cells. Cancer Immunol Immunother 1989;28:235-240.
9. LeBerthon B, Khawli LA, Alauddin M, Miller GK, Charak BS, Mazumder A, and Epstein AL. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res 1991;51:2694-2698.
10. Epstein AL and Khawli LA. Tumor biology and monoclonal antibodies: Overview of basic principles and clinical considerations. Antibody Immunoconj Radiopharm 1991;4:373-384
11. Lane D and Koprowski H Molecular recognition and the future of monoclonal antibodies. Nature 1982;296:200-202
12. Parham P. On the fragmentation of monoclonal IgG1, IgG2a and IgG2b from Balb/c mice J Immunol 1983;131:2895-2902.
13. 2. J Nucl Med 1983;24:316-325.
14. Wilbanks AB, Peterson JA, Miller S, Kaufman L, Ortendahl D, and Ceriani L. Localization of mammary tumors in vivo with I-131 labeled Fab fragments of antibodies against mouse mammary epithelial (MME) antigens. Cancer 1981;48:1768-1775.
15. Imoto H, Sakamura Y, Ohkouchi K, Atsumi R, Takakura Y, Sezaki H, and Hashida M. Disposition characteristics of macromolecules in the perfused tissue-isolated tumor preparation Cancer Res 1992152:4396-4401.
16. Khaw B-A, Klibanov A, O'Donnell SM, Saito T, Nossiff N, Slikin MA, Newell JB, Strauss HW, and Torchilin VP. Gamma imaging with negatively charge-modified monoclonal antibody: Modification with synthetic polymers. J Nucl Med 1991;32:1742-1751.
17. Kassis AI Optimizing antibodies for use in nuclear medicine. J Nucl Med 1991;32:1751-1753.
18. Eichmann K, Lackland H, Hood L, and Krause RM. Induction of rabbit antibody with molecular uniformity after immunization with group C streptococci. J Exp Med 1970;131.207-221.
19. Silva Filho FC, Santos ABS, de Carvalho TMU, and de Souza W. Surface charge of resident, elicited and activated mouse peritoneal macrophages. J Leukocyte Biol 1987;41:143-149.
20. Epstein AL, Marder RJ, Winter JN, Stathopoulos E, Chen F-M, Parker JW, and Taylor CR. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47:830-840
21. Miller GK, Naeve GS, Gaffar SA, and Epstein AL. Immunologic and biochemical analysis of TNT-1 and TNT-2 monoclonal antibody binding to histones. Hybridoma 1993;12:689-698.
22. Colcher D, Horan Hand P, Nuti M, and Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981;78.3199-3203.
23. Keenan AM, Colcher D, Larson SM, and Schlom J. Radioimmunoscintigraphy of human colon cancer xenografts in mice with radioiodinated monoclonal antibody B72.3. J Nucl Med 1984;25:1197-1203.
24. Colcher D, Keenan AM, Larson SM, and Schlom J. Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. Cancer Res 1984;44:5744-5751.
25. Chen F-M, Liu C-Z, Gaffar SA, and Epstein AL. Chromatographic methods for large-scale preparation of immunoglobulin G2a monoclonal antibodies Lym-1 and TNT-1 F(ab′)2 fragments. J Chromat 1991;563.243-255.
26. Milenic DE, Esteban JM, and Colcher D. Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72 3) reactive with human carcinomas. J Immunol Methods 1989;120:71-83.
27. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685
28. Carlsson J, Drevin H, and Axen R. Protein thiolation and reversible protein-protein conjugation. N-succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent Biochem J 1978;173:723-737.
29. Grassetti DR and Murray JF. Determination of sulfhydryl groups with 2,2′- or 4,4′-dithiodipyridine. Arch Biochem Biophys 1967;119:41-49.
30. McFarlane AJ. Labeling of plasma proteins with radioactive iodine. Biochem J 1956,62:135-143
31. Gaffar SA, Chen F-M, Liu C, and Epstein AL. Cell based radioimmunoassay to quantitate the immunoreactivity of TNT monoclonal antibodies directed against intracellular antigens. J Immunoassay 1991;2.11-14.
32. Epstein AL, Chen F-M, and Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988;48:5842-5848.
33. Khawli LA, Alauddin MM, Miller GK, and Epstein AL Improved immunotargeting of tumors with biotinylated monoclonal antibodies and radiolabeled streptavidin. Antibody Immunoconj Radiopharm 1993;6:13-27.
34. Khawli LA, Van den Abbeele AD, and Kassis AI. N-(m-[I- 125]Iodophenyl)maleimide: An agent for high yield radiolabeling of antibodies. Nucl Med Biol 1992;19:289-295.
35. Khawli LA, Chen F-M, Alauddin M, and Epstein AL Radioiodinated monoclonal antibody conjugates: Synthesis and comparative evaluation. Antibody, Immunoconjugates and Radiopharmaceuticals 1991;4:163-182.
36. Torchilin VP, Klibanov AL, Nossiff ND, Slikin MA, Strauss HW, Haber E, Smirnov VN, and Khaw B-A Monoclonal antibody modification with chelate-linked high molecular-weight polymers: Major increases in polyvalent cation binding without loss of antigen binding. Hybridoma 1987;6:229-240.
37. Gangopadhyay A, Van den Abbeele A, and Kassis AI. Modification of mouse IgG isoelectric point following radioiodination. Antibod Immunoconj Radiopharm 1994,7:171-178, 1994.
38. John E, Wilder S, Thakur ML, Alauddin MM, and Epstein AL Tc-99m labeled monoclonal antibodies: influence of Tc-99m binding sites. Nucl Med Comm 1994;35:876-881.
39. Seymour LW, Flanagan PA, Al-Shamkhani A, Subr V, Ulbrich K, Cassidy J, and Duncan R. Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumour-targeted drug delivery. Select Cancer Therapeut 1991;7:59-73.
40. Vitetta ES, Fulton RJ, May RD, Till M, and Uhr JW. Redesigning nature's poisons to create anti-tumor reagents. Science 1987;238:1098-1104.
41. Orlandi R, Canevari S, Leoni F, Mezzanzanica D, Ripamonti M, and Colnaghi M Change in binding reactivity of an anti-tumor monoclonal antibody after the introduction of 2-pyridyl disulphide groups. Hybridoma 1986;5:1-8
42. 2. Proc Natl Acad Sci USA 19901;87.5702-5705.
43. Khawli LA, Miller GK, and Epstein AL. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer (suppl.) 1993;73:824-831
44. Kuhn JA, Beatty BG, Wong JYC, Esteban JM, Wanek PM, Wall F, Buras RR, Williams LE, and Beatty JD Interferon enhancement of radioimmunotherapy for colon carcinoma. Cancer Res 1991;51:2335-2339.
45. Schlom J, Hand PH, Greiner JW, Colcher D, Shrivastav S, Carrasquillo JA, Reynolds JC, Larson SM, and Raubitschek A. Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Res 1990;50:820s-827s.